Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > So
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(27)
•••
Comment by PTBaileyon Apr 21, 2022 3:30pm
112 Views
Post# 34621527

RE:RE:So

RE:RE:So
Canary001 wrote: I am a share guy. Don't want warrants. This stock is going to go to the moon and I just love the volume. Up again like crazy today. As long as the price is low I am a happy man so I can buy and buy. Keep up the bashing - the price is stable and I know you can do a better job. 


Just in case you have no idea what Red One is talking about, all the comments he is making is because he thinks you are me. Not sure if you should be insulted or flattered.

He doesn't even realize he continues to humilliate himself by doing so because he thinks half the people on here are me. He doesn't realize I work, run my own business, don't have time for these childish games and don't care if people know who I am or not, which is why I use my real name.

He is a classic case so self-projection, he projects on to others what he himself does. He will copy his own posts from another site and post them here and say, "saw this on another site." LOL

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities